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Iron metabolism is well regulated in humans by a number of proteins, the most important one being hepcidin.1,2 Hepcidin inhibits iron absorption at the gastrointestinal (GI) luminal 
surface through its inhibition of ferroportin.1 Body 
iron stores, as well as inflammation, increase the 
level of hepcidin, thereby leading to decreased 
GI iron absorption. Additionally, high hepcidin 
levels lead to immobilization of iron within the 
reticuloendothelial system, specifically, the spleen 
and liver.3 The strict regulation of iron metabolism 
and the immobilization of iron during inflammation 
may have developed in animals and humans as a 
protective mechanism against infection by limiting 
the availability of iron to the infecting organism. 
The average daily GI absorption is 1–2 mg, which 
is similar to the amount shed out by the sloughing 
of epithelial cells in the GI system. Menstruating 
females lose an additional 20–40 mg every month. 
Other than this, humans are not equipped with any 
other way of removing iron.4
Hemosiderosis is a state of iron overload in 
different tissues and organs of the body.5 The 
causes of this are either hereditary (i.e., hereditary 
hemochromatosis), or iatrogenic as in patients who 
require frequent blood transfusions.6 Transfusion-
dependent thalassemia (TDT) is a group of genetic 
disorders characterized by decreased globin chain 
production of which the commonest is β-thalassemia 
major (β-TM). β-TM is characterized by the absence 
or severe reduction of β-globin chain production 
leading to globin chain imbalance, dyserythropoiesis, 
and severe anemia.7 These patients require regular 
blood transfusion to survive. Unfortunately, the 
necessary blood transfusions lead to a number 
of complications particularly iron overload and 
transfusion-transmitted viral infections such 
as hepatitis B and C, in addition to the human 
immunodeficiency virus.7
Animals and humans limit the toxicity of iron 
by containing it in a storage form to be mobilized 
when needed.4 However, when the degree of iron 
overload is beyond the storage capacity, it becomes 
freely bioavailable and toxic to different tissues 
and organs through the formation of free radicals.4 
The cellular damage caused by iron overload in 
patients with TDT leads to complications such as 
endocrinopathies, cardiac failure, and hepatic iron 
overload with subsequent cirrhosis. The development 
of iron chelators, namely, deferoxamine, deferiprone, 
and deferasirox (the three chelators currently 
available in Oman) have led to a marked reduction in 
the risk of iron-related complications and improved 
the survival of these patients.8,9
The gold standard for the diagnosis of hepatic iron 
overload is a liver biopsy. However, this is invasive, 
associated with bleeding and other morbidities and 
cannot be frequently performed.10 Although iron-
related cardiac disease is the commonest cause of 
death in TDT, there has, until recently, been no 
easily and safe way to assess myocardial iron. In 
2000, a special sequence of magnetic resonance 
imaging (MRI) called T2* was developed as a non-
invasive assessment of hepatic and cardiac iron 
overload.11 T2*MRI has become an essential tool in 
the management of iron overload in TDT, allowing 
physicians to safely and easily diagnose iron overload 
in both the liver and the heart, and to institute 
appropriate chelation strategies.
In this issue of the Oman Medical Journal, 
Soltanpour et al,12 reported a study that examined 
the association between cardiac and hepatic T2*MRI 
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in a cross-sectional design. As has been reported by 
other authors, they found a poor association of iron 
status between the two organs.13 The authors rightly 
concluded that the lack of association is probably 
related to the different rates of accumulation and 
clearance of cardiac and hepatic iron. It has been 
shown in a number of studies that the accumulation 
and clearance of cardiac iron in patients with TDT 
is slower than the hepatic clearance.13 Soltanpour et 
al,12 emphasize the importance of cardiac T2*MRI 
in the assessment of iron overload in patients with 
TDT. We agree that the use of T2*MRI should be 
the standard of care for these patients and centers 
should endeavor to make this available for the 
optimum care of patients with TDT.
The second finding reported in the study by 
Soltanpour et al,12 was the association between the 
human hemochromatosis protein (HFE) gene related 
mutations and iron overload in patients with TDT. 
In this study, patients carrying the H63D mutation 
had a much higher serum ferritin compared to those 
without the mutation (1903±993 vs. 992±683, p < 
0.001). They also found that the prevalence of the 
H63D mutation to be 20% in patients with β-TM. 
This is higher than expected in this region.14 However, 
it has clearly contributed to the increased absorption 
of GI iron. The mechanism of the increased 
absorption is, again, related to hepcidin. The HFE 
protein is an iron-specific adaptor that facilitates 
communication between transferrin receptor 1 and 
2 leading to downward signaling and ultimately 
increased transcription of hepcidin. Mutations in 
the HFE gene, namely C282Y and H63D, lead to 
the disruption of this function, and subsequently, to 
the decreased level of hepcidin and increased GI iron 
absorption.1 This by itself leads to the iron overload 
in patients with hereditary hemochromatosis. In 
patients with TDT, iron overload is mainly due to 
the transfused iron, but increased absorption is an 
additional factor. The increased GI iron absorption is 
driven by the increased erythropoietic requirement, 
a hepcidin related mechanism. Additionally, the 
disruption of the downward signaling in patients 
with the HFE mutations further suppresses hepcidin 
transcription leading to even further increased GI 
iron absorption. The unexpectedly high rate of the 
H63D mutation in the sample studied by Soltanpour 
et al,12 argues for testing patients with TDT in Oman. 
However, the impact on therapeutic decision-making 
is yet to be studied.
In summary, patients with TDT develop iron 
overload from frequent and necessary blood 
transfusion in addition to the increased absorption 
due to the increased erythropoietic requirement 
and potentially mutations in the HFE gene. Cross-
sectional studies are not optimal to study the association 
between hepatic and cardiac iron overload due to the 
different rates of iron accumulation and clearance. 
Further studies are needed to elucidate the prevalence 
of the HFE mutations in the Omani population.
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